Klexane

Enoxaparin sodium, the active ingredient in Klexane, is a low molecular weight heparin presented as a sterile solution for subcutaneous and intravenous use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and other thromboembolic disorders in at‑risk patients.

GNH USA supplies Klexane as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, supporting patient care across multiple continents and regulatory environments, and ensuring consistent quality throughout.

Enoxaparin sodium is a low molecular weight heparin used in the prevention and treatment of venous thromboembolism.

Deep vein thrombosis: prevention and treatment of DVT in surgical and medical patients. Pulmonary embolism: treatment of acute PE and prevention of recurrence. Venous thromboembolism prophylaxis: prophylaxis after orthopedic or abdominal surgery. Anticoagulation during hemodialysis: provides anticoagulation for patients undergoing haemodialysis. Acute coronary syndromes: adjunct anticoagulant therapy in ACS management.

Enoxaparin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site bruising or pain. - Minor bleeding such as epistaxis or gum bleeding. - Nausea or mild gastrointestinal discomfort. - Headache. - Transient elevation of liver enzymes. - Local erythema at the injection site.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as rash, urticaria, or anaphylaxis. - Spinal or epidural hematoma following neuraxial procedures. - Severe hypotension. - Skin necrosis at the injection site.

Before initiating enoxaparin therapy, several safety considerations are essential.

Renal impairment: adjust dose or monitor anti‑Xa activity in patients with reduced kidney function. Bleeding risk: assess for active bleeding or high‑risk lesions prior to use. Pregnancy: category B; use only when the clinical benefit outweighs potential risk. Surgery or invasive procedures: discontinue appropriately before major operations to reduce bleeding. Concomitant anticoagulants: avoid combined use with other anticoagulants unless clinically indicated. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin can interact with other medicines, affecting bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Concurrent unfractionated heparin: additive anticoagulation increases bleeding. - Combined warfarin therapy: potentiates anticoagulant effect and raises INR. - Use with potent antiplatelet agents (e.g., clopidogrel) in high‑bleeding‑risk patients.

Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen): may increase minor bleeding. - Thrombolytic agents (alteplase, streptokinase): additive anticoagulant effect. - SSRIs or SNRIs (fluoxetine, venlafaxine): potential for increased bleeding tendency.